Cytochrome P4501A2 phenotype and bladder cancer risk: The Shanghai bladder cancer study

International Journal of Cancer

Volumn 130, Issue 5, 2012, Pages 1174-1183

  Tao, Li ^a   Xiang, Yong Bing ^b   Chan, Kenneth K ^c   Wang, Renwei ^a   Gao, Yu Tang ^b   Yu, Mimi C ^a   Yuan, Jian Min ^a,d  

^a UNIVERSITY OF MINNESOTA   (United States)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c OHIO STATE UNIVERSITY   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; CAFFEINE; CYTOCHROME P450 1A2;

ACETYLATION; ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER RISK; CASE CONTROL STUDY; CHINA; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; URINALYSIS;

AGED; ARYLAMINE N-ACETYLTRANSFERASE; CASE-CONTROL STUDIES; CHINA; CYTOCHROME P-450 CYP1A2; FEMALE; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; RISK FACTORS; SMOKING; URINARY BLADDER NEOPLASMS;

EID: 84155167905     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26121     Document Type: Article

References (49)

1. Centers for Disease Control and Prevention. The Health Consequences of Smoking: A Report of the Surgeon General. Centers for Disease Control and Prevention, Office on Smoking and Health, 2004.
2. Silverman DT, Devesa SS, Moore LL, Rothman N,. Bladder cancer. In:, Schottenfeld D, Fraumeni JJ, eds. Cancer epidemiology and preventioned, New York, NY: Oxford University Press, 2006, pp. 1101-27.
3. IARC. Reversal of risk after quitting smoking: IARC handbook of cancer prevention, 2007.
4. Hecht SS,. Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat Rev Cancer 2003; 3: 733-44. (Pubitemid 37328812)
5. Yu MC, Skipper PL, Tannenbaum SR, Chan KK, Ross RK,. Arylamine exposures and bladder cancer risk. Mutat Res 2002; 506,507: 21-8. (Pubitemid 35286536)
6. Butler MA, Lang NP, Young JF, Caporaso NE, Vineis P, Hayes RB, Teitel CH, Massengill JP, Lawsen MF, Kadlubar FF,. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 1992; 2: 116-27.
7. Schweikl H, Taylor JA, Kitareewan S, Linko P, Nagorney D, Goldstein JA,. Expression of CYP1A1 and CYP1A2 genes in human liver. Pharmacogenetics 1993; 3: 239-49. (Pubitemid 23333093)
8. Butler MA, Guengerich FP, Kadlubar FF,. Metabolic oxidation of the carcinogens 4-aminobiphenyl and 4,4′-methylene-bis(2-chloroaniline) by human hepatic microsomes and by purified rat hepatic cytochrome P-450 monooxygenases. Cancer Res 1989; 49: 25-31.
9. Pavanello S, Simioli P, Lupi S, Gregorio P, Clonfero E,. Exposure levels and cytochrome P450 1A2 activity, but not N-acetyltransferase, glutathione S-transferase (GST) M1 and T1, influence urinary mutagen excretion in smokers. Cancer Epidemiol Biomarkers Prev 2002; 11: 998-1003. (Pubitemid 35192649)
10. Rasmussen BB, Brix TH, Kyvik KO, Brosen K,. The interindividual differences in the 3-demthylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors. Pharmacogenetics 2002; 12: 473-8. (Pubitemid 34913530)
11. Nakajima M, Yokoi T, Mizutani M, Kinoshita M, Funayama M, Kamataki T,. Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J Biochem 1999; 125: 803-8. (Pubitemid 29192503)
12. Castorena-Torres F, Mendoza-Cantu A, de Leon MB, Cisneros B, Zapata-Perez O, Lopez-Carrillo L, Salinas JE, Albores A,. CYP1A2 phenotype and genotype in a population from the Carboniferous Region of Coahuila, Mexico. Toxicol Lett 2005; 156: 331-9. (Pubitemid 40342566)
13. Chen X, Wang L, Zhi L, Zhou G, Wang H, Zhang X, Hao B, Zhu Y, Cheng Z, He F,. The G-113A polymorphism in CYP1A2 affects the caffeine metabolic ratio in a Chinese population. Clin Pharmacol Ther 2005; 78: 249-59. (Pubitemid 41254110)
14. Sachse C, Bhambra U, Smith G, Lightfoot TJ, Barrett JH, Scollay J, Garner RC, Boobis AR, Wolf CR, Gooderham NJ,. Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: Allele frequencies, linkage disequilibrium and influence on caffeine metabolism. Br J Clin Pharmacol 2003; 55: 68-76. (Pubitemid 36110841)
15. Jiang Z, Dragin N, Jorge-Nebert LF, Martin MV, Guengerich FP, Aklillu E, Ingelman-Sundberg M, Hammons GJ, Lyn-Cook BD, Kadlubar FF, Saldana SN, Sorter M, et al,. Search for an association between the human CYP1A2 genotype and CYP1A2 metabolic phenotype. Pharmacogenet Genomics 2006; 16: 359-67.
16. Lee SJ, Cho SH, Park SK, Kim SW, Park MS, Choi HY, Choi JY, Lee SY, Im HJ, Kim JY, Yoon KJ, Choi H, et al,. Combined effect of glutathione S-transferase M1 and T1 genotypes on bladder cancer risk. Cancer Lett 2002; 177: 173-9. (Pubitemid 34127918)
17. Hein DW,. Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutat Res 2002; 506,507: 65-77. (Pubitemid 35286541)
18. Garcia-Closas M, Malats N, Silverman D, Dosemeci M, Kogevinas M, Hein DW, Tardon A, Serra C, Carrato A, Garcia-Closas R, Lloreta J, Castano-Vinyals G, et al,. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 2005; 366: 649-59. (Pubitemid 41176017)
19. Green J, Banks E, Berrington A, Darby S, Deo H, Newton R,. N-acetyltransferase 2 and bladder cancer: an overview and consideration of the evidence for gene-environment interaction. Br J Cancer 2000; 83: 412-7. (Pubitemid 30453586)
20. Cartwright RA, Glashan RW, Rogers HJ, Ahmad RA, Barham-Hall D, Higgins E, Kahn MA,. Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer. Lancet 1982; 2: 842-5.
21. Risch A, Wallace DM, Bathers S, Sim E,. Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. Hum Mol Genet 1995; 4: 231-6.
22. Fanlo A, Sinues B, Mayayo E, Bernal L, Soriano A, Martinez-Jarreta B, Martinez-Ballarin E,. Urinary mutagenicity, CYP1A2 and NAT2 activity in textile industry workers. J Occup Health 2004; 46: 440-7. (Pubitemid 40011862)
23. Carreon T, Ruder AM, Schulte PA, Hayes RB, Rothman N, Waters M, Grant DJ, Boissy R, Bell DA, Kadlubar FF, Hemstreet GP III, Yin S, et al,. NAT2 slow acetylation and bladder cancer in workers exposed to benzidine. Int J Cancer 2006; 118: 161-8. (Pubitemid 41681593)
24. Lee SW, Jang IJ, Shin SG, Lee KH, Yim DS, Kim SW, Oh SJ, Lee SH,. CYP1A2 activity as a risk factor for bladder cancer. J Korean Med Sci 1994; 9: 482-9.
25. Vaziri SA, Hughes NC, Sampson H, Darlington G, Jewett MA, Grant DM,. Variation in enzymes of arylamine procarcinogen biotransformation among bladder cancer patients and control subjects. Pharmacogenetics 2001; 11: 7-20. (Pubitemid 32108657)
26. Yuan JM, Chan KK, Coetzee GA, Castelao JE, Watson MA, Bell DA, Wang R, Yu MC,. Genetic determinants in the metabolism of bladder carcinogens in relation to risk of bladder cancer. Carcinogenesis 2008; 29: 1386-93.
27. Tang BK, Kadar D, Kalow W,. An alternative test for acetylator phenotyping with caffeine. Clin Pharmacol Ther 1987; 42: 509-13. (Pubitemid 18002167)
28. Grant DM, Tang BK, Kalow W,. Polymorphic N-acetylation of a caffeine metabolite. Clin Pharmacol Ther 1983; 33: 355-9. (Pubitemid 13089527)
29. Tang BK, Kadar D, Qian L, Iriah J, Yip J, Kalow W,. Caffeine as a metabolic probe: validation of its use for acetylator phenotyping. Clin Pharmacol Ther 1991; 49: 648-57.
30. Stram DO, Yuan JM, Chan KK, Gao YT, Ross RK, Yu MC,. Beta-cryptoxanthin and lung cancer in Shanghai, China - an examination of potential confounding with cigarette smoking using urinary cotinine as a biomarker for true tobacco exposure. Nutr Cancer 2007; 57: 123-9. (Pubitemid 47080083)
31. Skarping G, Willers S, Dalene M,. Determination of cotinine in urine using glass capillary gas chromatography and selective detection, with special reference to the biological monitoring of passive smoking. J Chromatogr 1988; 454: 293-301.
32. Rothman KJ,. The estimation of synergy or antagonism. Am J Epidemiol 1976; 103: 506-11.
33. Landi MT, Zocchetti C, Bernucci I, Kadlubar FF, Tannenbaum S, Skipper P, Bartsch H, Malaveille C, Shields P, Caporaso NE, Vineis P,. Cytochrome P4501A2: enzyme induction and genetic control in determining 4-aminobiphenyl-hemoglobin adduct levels. Cancer Epidemiol Biomarkers Prev 1996; 5: 693-8. (Pubitemid 26304643)
34. Skipper PL, Tannenbaum SR, Ross RK, Yu MC,. Nonsmoking-related arylamine exposure and bladder cancer risk. Cancer Epidemiol Biomarkers Prev 2003; 12: 503-7. (Pubitemid 36713643)
35. Ghotbi R, Christensen M, Roh HK, Ingelman-Sundberg M, Aklillu E, Bertilsson L,. Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. Eur J Clin Pharmacol 2007; 63: 537-46. (Pubitemid 46684487)
36. Sachse C, Brockmoller J, Bauer S, Roots I,. Functional significance of a C - >A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 1999; 47: 445-9. (Pubitemid 29161279)
37. Campbell ME, Spielberg SP, Kalow W,. A urinary metabolite ratio that reflects systemic caffeine clearance. Clin Pharmacol Ther 1987; 42: 157-65. (Pubitemid 17135971)
38. La Vecchia C, Negri E, Decarli A, D'Avanzo B, Liberati C, Franceschi S,. Dietary factors in the risk of bladder cancer. Nutr Cancer 1989; 12: 93-101. (Pubitemid 19055772)
39. Kunze E, Chang-Claude J, Frentzel-Beyme R,. Life style and occupational risk factors for bladder cancer in Germany. A case-control study. Cancer 1992; 69: 1776-90.
40. Lampe JW, King IB, Li S, Grate MT, Barale KV, Chen C, Feng Z, Potter JD,. Brassica vegetables increase and apiaceous vegetables decrease cytochrome P450 1A2 activity in humans: changes in caffeine metabolite ratios in response to controlled vegetable diets. Carcinogenesis 2000; 21: 1157-62. (Pubitemid 30389341)
41. Figueroa JD, Malats N, Garcia-Closas M, Real FX, Silverman D, Kogevinas M, Chanock S, Welch R, Dosemeci M, Lan Q, Tardon A, Serra C, et al,. Bladder cancer risk and genetic variation in AKR1C3 and other metabolizing genes. Carcinogenesis 2008; 29: 1955-62.
42. Altayli E, Gunes S, Yilmaz AF, Goktas S, Bek Y,. CYP1A2, CYP2D6, GSTM1, GSTP1, and GSTT1 gene polymorphisms in patients with bladder cancer in a Turkish population. Int Urol Nephrol 2009; 41: 259-66.
43. Yu MC, Skipper PL, Taghizadeh K, Tannenbaum SR, Chan KK, Henderson BE, Ross RK,. Acetylator phenotype, aminobiphenyl-hemoglobin adduct levels, and bladder cancer risk in white, black, and Asian men in Los Angeles, California. J Natl Cancer Inst 1994; 86: 712-6. (Pubitemid 24138978)
44. Castelao JE, Yuan JM, Skipper PL, Tannenbaum SR, Gago-Dominguez M, Crowder JS, Ross RK, Yu MC,. Gender- and smoking-related bladder cancer risk. J Natl Cancer Inst 2001; 93: 538-45. (Pubitemid 32318433)
45. Filiadis IF, Georgiou I, Alamanos Y, Kranas V, Giannakopoulos X, Lolis D,. Genotypes of N-acetyltransferase-2 and risk of bladder cancer: a case-control study. J Urol 1999; 161: 1672-5. (Pubitemid 29420860)
46. Cribb AE, Isbrucker R, Levatte T, Tsui B, Gillespie CT, Renton KW,. Acetylator phenotyping: the urinary caffeine metabolite ratio in slow acetylators correlates with a marker of systemic NAT1 activity. Pharmacogenetics 1994; 4: 166-70. (Pubitemid 24210936)
47. Sanderson Cox L, Sloan JA, Patten CA, Bonner JA, Geyer SM, McGinnis WL, Stella PJ, Marks RS,. Smoking behavior of 226 patients with diagnosis of stage IIIA/IIIB non-small cell lung cancer. Psychooncology 2002; 11: 472-8. (Pubitemid 36007918)
48. Ikeya K, Jaiswal AK, Owens RA, Jones JE, Nebert DW, Kimura S,. Human CYP1A2: sequence, gene structure, comparison with the mouse and rat orthologous gene, and differences in liver 1A2 mRNA expression. Mol Endocrinol 1989; 3: 1399-408. (Pubitemid 19241032)
49. Nakajima M, Yamamoto T, Nunoya K, Yokoi T, Nagashima K, Inoue K, Funae Y, Shimada N, Kamataki T, Kuroiwa Y,. Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab Dispos 1996; 24: 1212-7. (Pubitemid 26423061)